25.06.2012 • News

Lonza, Biowa Sign License Agreements with FivePrime Therapeutics

FivePrime Therapeutics has entered into research and commercial agreements with Biowa and Lonza to use their Potelligent CHOK1SV Cell Line for the research, development and production of multiple proprietary antibodies in FivePrime's oncology pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of Biowa's engineered glycosylation Potellingent Technology with the advantages of Lonza's proprietary GS Gene Expression Systems, which includes the industry-leading CHOK1SV cell line.

 

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.